How to transfer my Ozempic prescription to Illinois

If you’ve been researching weight loss options, you’ve likely heard about medications like Wegovy, Ozempic, and Mounjaro—powerful GLP-1 drugs that have transformed obesity treatment. And if you’re wondering whether you can get these medications through telehealth without visiting a doctor’s office in person, the short answer is: Yes, in most cases you can.

But as with many things in healthcare, the details matter. Federal and state regulations create a patchwork of rules that can affect your ability to access these medications remotely. This comprehensive guide will walk you through everything you need to know about getting GLP-1 weight loss prescriptions via telehealth in 2025.

Understanding the Basics: What Makes Telehealth Prescribing Legal?

Federal Law and Non-Controlled Medications

Here’s the most important thing to understand: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This is crucial because it means they’re not subject to the Ryan Haight Act—the federal regulation that typically requires an in-person medical examination before prescribing controlled medications via telehealth.

The Ryan Haight Act was created to prevent online ‘pill mills’ from distributing dangerous controlled substances like opioids or stimulants without proper medical oversight. Since semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) don’t fall into this category, federal law places no special restrictions on prescribing them through telehealth.

During the COVID-19 pandemic, the DEA temporarily waived in-person requirements even for controlled substances. That flexibility has been extended multiple times—most recently through December 31, 2025—to maintain access to medications like ADHD treatments and addiction medications. However, this extension doesn’t directly affect GLP-1 weight loss drugs, which were always prescribable via telehealth under federal law.

What This Means for You

If you’re in a state that permits telehealth for prescription medications (which is now all 50 states to some degree), a licensed healthcare provider can evaluate you through a video consultation, determine if you’re a good candidate for GLP-1 therapy, and electronically send a prescription to your pharmacy—all without requiring you to visit an office.

That said, state laws add another layer of requirements that can vary significantly depending on where you live.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Requirements: Where the Rules Get Complicated

While federal law allows telehealth prescribing of GLP-1 medications, individual states have the authority to impose additional requirements around telemedicine practice, prescriber qualifications, and obesity treatment protocols.

States Requiring an Initial In-Person Examination

Several states maintain rules that require at least one in-person visit before or shortly after starting weight loss medication therapy:

Arkansas has some of the strictest telehealth regulations in the country. State law requires an initial in-person examination to establish the doctor-patient relationship before prescribing weight loss medications via telehealth. Proposals to ease these restrictions have been under review, but as of late 2025, the in-person requirement remains in effect.

Delaware requires an initial physical examination in person before prescribing GLP-1 medications for weight loss. After that first visit, follow-up care can be conducted via telehealth.

Georgia mandates an in-person exam prior to telehealth prescribing of weight loss drugs. However, Georgia recently expanded prescriptive authority—as of July 2024, nurse practitioners and physician assistants can now prescribe Schedule II controlled substances with physician delegation, marking a significant shift in the state’s approach to advanced practice providers.

Mississippi requires patients to be seen at least once in person for weight management therapy. There’s ongoing legislative momentum to expand nurse practitioner independence and potentially ease some telehealth restrictions.

New Jersey has particularly comprehensive requirements: providers must conduct an extensive initial evaluation including a physical exam, laboratory work, psychological screening, and documentation of a personalized diet and exercise plan before prescribing any weight loss medication. The state’s Board of Medicine takes obesity treatment protocols seriously, requiring providers to identify and document risks associated with therapy.

North Dakota expects a hands-on initial evaluation for weight loss treatment, though the state otherwise embraces telehealth broadly. North Dakota is a full practice authority state for nurse practitioners, making access easier once the initial exam is completed.

South Carolina requires an initial in-person visit and periodic follow-up evaluations. Nurse practitioners and physician assistants can prescribe under medical supervision with written protocols.

Texas generally expects an in-person exam as part of establishing a valid physician-patient relationship for weight loss prescribing, consistent with the state’s standard of care for obesity treatment. Texas maintains strict oversight over advanced practice providers—nurse practitioners cannot practice independently and must work under physician delegation agreements.

Utah encourages an initial in-person baseline evaluation, though the state has become more flexible with telehealth. Utah granted nurse practitioners full practice authority in 2023, expanding access to care.

Virginia has detailed requirements: state regulations mandate an initial comprehensive physical examination, laboratory testing, and development of a diet and exercise plan before prescribing weight loss medications. Additionally, Virginia requires a follow-up visit within 30 days of starting therapy to assess tolerance and response.

States With No In-Person Requirements

Many states allow GLP-1 medications to be prescribed entirely through telehealth, with no requirement for an in-person visit:

California explicitly permits telehealth examinations as sufficient for prescribing. The state also grants nurse practitioners independent practice authority after three years of experience, making California one of the most accessible states for telehealth weight loss treatment.

Connecticut allows fully remote prescribing but requires that obesity treatment include behavioral counseling and a diet/exercise plan as part of comprehensive care.

Florida doesn’t require an in-person visit for telehealth prescribing, but state law imposes specific conditions: patients must have a BMI of 30 or higher (or 27 with comorbidities), and follow-up visits must occur at least every three months during treatment.

Illinois has no special in-person requirements for weight loss medications and has embraced permanent telehealth laws. The state does require electronic prescribing for all medications.

New York allows telehealth examinations to serve as the basis for prescribing, with no in-person mandate. New York is also a full practice authority state for nurse practitioners who have completed 3,600 hours of experience.

Pennsylvania places no in-person barriers to telehealth prescribing of GLP-1 medications. However, nurse practitioners still operate under physician collaboration agreements.

Washington is one of the most progressive telehealth states with no in-person requirements and full nurse practitioner independence. The state’s My Health My Data Act also imposes strong privacy protections for telehealth services—particularly important given the sensitive nature of weight loss treatment.

States With Ongoing Follow-Up Requirements

Even in states that don’t require an initial in-person visit, some mandate regular check-ins:

Florida requires patients to be evaluated at least once every three months during ongoing treatment.

Virginia mandates a 30-day follow-up after initiating therapy and continued regular monitoring.

These requirements reflect good clinical practice—GLP-1 medications require monitoring for side effects, dose adjustments, and effectiveness. Reputable telehealth providers like Klarity Health build these follow-ups into their care models as a standard practice, regardless of state requirements.

Who Can Prescribe GLP-1 Medications Via Telehealth?

Physicians (MDs and DOs)

All states allow medical doctors and doctors of osteopathic medicine to prescribe GLP-1 weight loss medications via telehealth, provided they hold an active license in the state where the patient is physically located.

Nurse Practitioners and Physician Assistants

The authority of nurse practitioners (NPs) and physician assistants (PAs) to prescribe these medications varies significantly by state:

Independent Practice States (Full Authority): As of 2025, 34 states plus the District of Columbia grant nurse practitioners full practice authority, meaning they can evaluate patients, diagnose conditions, and prescribe medications independently without physician oversight. These states include:

• Arizona
• California
• Colorado
• Connecticut
• Delaware
• Hawaii
• Idaho
• Iowa
• Maryland
• Montana
• Nebraska
• Nevada
• New Hampshire
• New Mexico
• New York
• North Dakota
• Oregon
• Rhode Island
• Utah
• Vermont
• Washington
• Wyoming

Some states require a transitional period of supervised practice (typically 2-3 years) before granting full independence.

Collaborative/Reduced Practice States: Many states allow NPs and PAs to prescribe but require some form of physician collaboration, supervision agreement, or protocol:

• Arkansas
• Florida
• Georgia
• Illinois
• Mississippi
• New Jersey
• Pennsylvania
• South Carolina
• Texas
• Virginia

The specific requirements vary—some states require formal written agreements, while others mandate periodic chart reviews or consultation availability.

Texas deserves special mention: The state maintains particularly restrictive requirements for advanced practice providers. NPs must work under physician delegation agreements and cannot prescribe certain medications independently. While GLP-1 drugs can be prescribed by Texas NPs (since they’re not controlled substances), the oversight requirements are more stringent than most states.

What This Means for Your Care

If you’re using a telehealth platform, you may be matched with a physician, nurse practitioner, or physician assistant depending on availability and your state’s regulations. This is perfectly normal and legal—all these providers are qualified to manage obesity treatment when practicing within their scope.

Klarity Health works exclusively with licensed, credentialed providers who are authorized to practice in your state, ensuring your care meets all legal and professional standards.

Clinical Eligibility: Who Qualifies for GLP-1 Medications?

Understanding the legal framework is only half the picture. Even in states with no telehealth barriers, you must meet clinical criteria to receive these powerful medications.

Standard Medical Criteria

FDA-approved indications for GLP-1 weight loss medications typically include:

Body Mass Index (BMI) Requirements:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea)

Additional Considerations:

• Adults 18 years and older (some medications now have pediatric indications for ages 12+)
• Previous attempts at lifestyle modification (diet and exercise) without sufficient weight loss
• Absence of contraindications (discussed below)
• Commitment to ongoing lifestyle changes alongside medication

Contraindications and Disqualifying Conditions

Reputable telehealth providers will screen carefully for conditions that make GLP-1 therapy unsafe:

Absolute Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or active plans to become pregnant
• Previous serious hypersensitivity reaction to the medication

Relative Contraindications (require careful evaluation):

• History of pancreatitis
• Severe gastroparesis or gastrointestinal disorders
• Active gallbladder disease
• Diabetic retinopathy (particularly with rapid glycemic changes)
• History of suicidal ideation (requires psychiatric evaluation)
• Eating disorders

The Evaluation Process

A legitimate telehealth consultation for GLP-1 medications should include:

1. Comprehensive Medical History: Current and past medical conditions, surgical history, medication list, allergies
2. Weight History: Previous weight loss attempts, timeline of weight gain, dietary patterns
3. Vital Information: Current weight, height, blood pressure (self-reported or verified)
4. Mental Health Screening: Assessment for depression, eating disorders, body image issues
5. Lifestyle Assessment: Current diet, exercise habits, sleep, stress levels
6. Informed Consent: Discussion of potential side effects, realistic expectations, alternatives

Many states require documentation of this comprehensive evaluation. Even where not legally mandated, thorough assessment is the standard of care.

Laboratory Testing

Depending on your state and individual health status, providers may require recent lab work:

• Baseline metabolic panel: To assess kidney and liver function
• Thyroid function tests: Particularly if symptoms suggest thyroid issues
• Hemoglobin A1C: For patients with diabetes or prediabetes
• Lipid panel: To document cardiovascular risk factors

Some states like New Jersey and Virginia explicitly require laboratory testing as part of the initial evaluation. Even where not required, responsible providers will order labs for patients with certain risk factors.

Medication Overview: Understanding Your Options

Wegovy (Semaglutide 2.4mg)

FDA Status: Approved specifically for chronic weight management in adults with obesity or overweight with comorbidities

How It Works: Once-weekly subcutaneous injection; GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves blood sugar control

Typical Dosing: Gradual titration starting at 0.25mg weekly, increasing every 4 weeks to a maintenance dose of 2.4mg

Expected Results: Clinical trials showed average weight loss of 15-17% of body weight over 68 weeks when combined with lifestyle modification

Telehealth Prescribing: Fully legal via telehealth in all states (subject to state-specific requirements for evaluation and follow-up)

Important Note: Wegovy has periodically experienced supply shortages. During shortages, some patients were prescribed Ozempic off-label; however, as of 2025, supply has improved significantly.

Ozempic (Semaglutide 0.5mg, 1mg, 2mg)

FDA Status: Approved for type 2 diabetes management; frequently prescribed off-label for weight loss

How It Works: Identical mechanism to Wegovy (same active ingredient, semaglutide), but in different doses and FDA-approved for a different indication

Off-Label Use: Many providers prescribe Ozempic for weight loss when Wegovy is unavailable or not covered by insurance. This is legal and common practice, but requires informed consent and documentation of the off-label use rationale.

Prescribing Considerations: When prescribed for weight loss in patients without diabetes, this is explicitly off-label use. Telehealth providers must document medical necessity and discuss alternatives with patients.

Mounjaro (Tirzepatide) and Zepbound

FDA Status: Mounjaro is approved for type 2 diabetes; Zepbound (same drug, different branding) received FDA approval for chronic weight management in late 2023

How It Works: Dual GLP-1 and GIP receptor agonist—works on two hormone pathways instead of one, potentially offering greater efficacy

Dosing: Once-weekly injection with gradual titration; maintenance doses range from 5mg to 15mg

Expected Results: Clinical trials showed average weight loss of 20-22% of body weight—among the highest of any anti-obesity medication

Telehealth Prescribing: Permitted via telehealth; if prescribed as Mounjaro for weight loss in non-diabetic patients, this constitutes off-label use and requires appropriate documentation

Compounded Semaglutide: What You Need to Know

Until recently, some telehealth companies offered ‘compounded’ versions of semaglutide at lower costs during FDA-designated shortages of Wegovy and Ozempic. However, in May 2025, the FDA declared the shortage resolved and effectively banned routine compounding of semaglutide for weight loss.

This FDA action specifically targeted compounding pharmacies creating copies of the brand-name drugs. The ruling forced several telehealth companies to discontinue their compounded semaglutide programs, impacting access for patients who relied on these more affordable options.

Current Status: Legitimate compounding of semaglutide is now extremely limited—only allowed in narrow circumstances such as documented patient allergy to inactive ingredients in the commercial products. Most telehealth providers have discontinued compounded offerings.

Why This Matters: If you encounter a telehealth service still offering ‘cheap compounded semaglutide,’ this is a major red flag. Such products may be:

• Illegally compounded in violation of FDA regulations
• Of questionable quality or potency
• Sourced from overseas suppliers without FDA oversight
• Potentially contaminated or mislabeled

Always insist on FDA-approved, brand-name medications from licensed U.S. pharmacies.

The Telehealth Prescribing Process: What to Expect

Step 1: Platform Registration and Medical Intake

You’ll start by creating an account with a telehealth provider and completing a comprehensive medical questionnaire. Expect questions about:

• Your weight history and previous weight loss attempts
• Current medications and supplements
• Medical conditions and surgical history
• Allergies and adverse reactions
• Family medical history (particularly thyroid cancer, diabetes)
• Mental health and eating patterns
• Lifestyle factors (diet, exercise, sleep, stress)

This intake typically takes 15-30 minutes to complete thoroughly. Rushing through or providing incomplete information can delay care or result in inappropriate prescribing.

Step 2: Provider Consultation

You’ll schedule a live video consultation (or in some cases, a phone consultation where permitted) with a licensed provider. This visit typically lasts 20-45 minutes for initial evaluations.

What Happens During the Visit:

• Review of your medical history and weight loss goals
• Discussion of realistic expectations and timeline
• Education about how GLP-1 medications work
• Review of potential side effects and contraindications
• Screening for mental health concerns
• Assessment of your commitment to lifestyle changes
• Informed consent process
• Discussion of alternatives (other medications, procedures, behavioral interventions)

In-Person Requirements: If your state requires an initial in-person exam, the telehealth provider will coordinate this. Some platforms have partnerships with local clinics or labs; others may accept documentation from your primary care provider.

Step 3: Prescription and Pharmacy

If the provider determines you’re a good candidate, they’ll electronically transmit the prescription to your chosen pharmacy. Many states now mandate electronic prescribing for all medications.

Pharmacy Options:

• Local retail pharmacy (CVS, Walgreens, Kroger, etc.)
• Mail-order pharmacy (especially useful for 90-day supplies)
• Specialty pharmacy (required by some insurance plans for expensive medications)

Insurance Considerations: Coverage for GLP-1 weight loss medications varies widely. Medicare Part D generally does not cover weight loss medications, though it does cover diabetes drugs. Commercial insurance coverage is expanding but often requires prior authorization and documentation of medical necessity.

Cost Transparency: Reputable telehealth platforms like Klarity Health provide transparent pricing, accept both insurance and self-pay options, and help patients understand their out-of-pocket costs before committing to treatment.

Step 4: Medication Training and Initiation

GLP-1 medications are self-injected (usually in the abdomen or thigh). First-time users need training on:

• Proper injection technique
• Needle safety and disposal
• Medication storage (refrigeration requirements)
• Dose escalation schedule
• What to do if you miss a dose
• Managing common side effects

Many telehealth platforms provide video tutorials, written guides, and ongoing support through patient portals or messaging systems.

Step 5: Ongoing Monitoring and Follow-Up

Regular follow-up is essential—both for medical safety and, in many states, as a legal requirement:

Initial Follow-Up: Most providers schedule a check-in 2-4 weeks after starting medication to assess:

• Tolerance of the medication
• Side effects
• Initial weight response
• Need for dose adjustment

Ongoing Monitoring: Follow-up visits typically occur every 4-12 weeks (depending on state requirements and clinical stability) to monitor:

• Weight trends
• Blood pressure and other vitals
• Side effects or complications
• Adherence to medication and lifestyle plan
• Labs if indicated (metabolic panel, A1C)
• Mental health and motivation

Duration of Treatment: GLP-1 medications are generally intended for long-term use. Weight regain is common if medication is discontinued without maintenance strategies. Your provider will work with you to develop a sustainable long-term plan.

Red Flags: How to Identify Questionable Telehealth Providers

The popularity of GLP-1 medications has unfortunately attracted some bad actors. Here’s what to watch out for:

Prescription Guarantees

Red Flag: Any service that guarantees you’ll receive a prescription before you’ve even completed an evaluation.

Why It Matters: Responsible medical care requires individualized assessment. No legitimate provider can promise a prescription without knowing your full medical history and determining if the medication is appropriate and safe for you.

Minimal or No Medical Evaluation

Red Flag: Services that don’t require a comprehensive intake questionnaire, skip the video consultation, or conduct only cursory 5-minute ‘consultations.’

Why It Matters: GLP-1 medications have significant contraindications and potential side effects. Proper prescribing requires thorough evaluation of your medical history, current health status, and risk factors.

Compounded or ‘Generic’ Semaglutide

Red Flag: Offerings of compounded, ‘generic,’ or imported versions of semaglutide at unusually low prices.

Why It Matters: As of 2025, FDA-approved versions are available and compounding is no longer permitted except in narrow circumstances. Products marketed as ‘cheaper alternatives’ may be illegal, unsafe, or ineffective.

No Follow-Up or Monitoring

Red Flag: Services that prescribe medication but don’t schedule follow-up visits or offer ongoing monitoring.

Why It Matters: These medications require monitoring for safety and effectiveness. Lack of follow-up is medically inappropriate and, in some states, illegal.

Unclear Provider Credentials or Licensing

Red Flag: Platforms that don’t clearly identify the prescribing provider by name, credentials, and state license number, or that are evasive about where providers are licensed.

Why It Matters: Your provider must be licensed in the state where you’re physically located. Prescribing across state lines without proper licensure is illegal.

Pressure Tactics or Aggressive Marketing

Red Flag: High-pressure sales tactics, claims that ‘everyone qualifies,’ or marketing that focuses on rapid weight loss without mentioning risks or lifestyle changes.

Why It Matters: Legitimate medical services prioritize informed decision-making and patient safety over sales.

Missing Privacy Protections

Red Flag: Lack of clear privacy policies, absence of HIPAA compliance statements, or requests for sensitive information over unsecured channels.

Why It Matters: Your medical information is protected by federal law. Providers must use secure, HIPAA-compliant systems for all communications and data storage.

Privacy and Data Security Considerations

Weight loss is a deeply personal matter, and your telehealth provider handles sensitive information about your body, health conditions, and potentially mental health. Understanding privacy protections is crucial.

Federal HIPAA Protections

The Health Insurance Portability and Accountability Act (HIPAA) establishes national standards for protecting medical records and personal health information. All healthcare providers, including telehealth platforms, must comply with HIPAA requirements:

• Secure storage and transmission of medical data
• Limited disclosure of health information
• Patient rights to access their records
• Notification requirements in case of data breaches

State Privacy Laws

Some states have enacted additional consumer privacy protections that go beyond HIPAA:

Washington’s My Health My Data Act (2023) imposes strict requirements on businesses collecting health data, including telehealth providers. It requires explicit consent for data collection, limits data sharing, and gives consumers enhanced rights over their health information.

Other states with enhanced health data privacy laws include California (with its comprehensive CCPA protections) and Virginia (Consumer Data Protection Act).

What to Ask Your Telehealth Provider

• How is my medical information stored and secured?
• Who has access to my health records?
• Will my information be shared with third parties (insurance, employers, marketing companies)?
• What happens to my data if I discontinue service?
• How can I access or delete my health information?

Klarity Health maintains HIPAA-compliant systems, uses encrypted communications for all patient interactions, and provides transparent information about data handling in our privacy policy.

Insurance Coverage and Cost Considerations

Insurance Coverage Landscape

Coverage for GLP-1 weight loss medications varies significantly:

Medicare: Generally does NOT cover weight loss medications (including Wegovy). Medicare Part D does cover diabetes medications like Ozempic for patients with type 2 diabetes.

Medicaid: Coverage varies by state. Some state Medicaid programs cover Wegovy or similar medications with prior authorization; others exclude weight loss drugs entirely.

Commercial Insurance: Many private insurance plans now cover GLP-1 medications for weight loss, but typically with requirements:

• Prior authorization (documentation of BMI, comorbidities, previous weight loss attempts)
• Step therapy (trying other weight loss interventions first)
• Quantity limits (e.g., 1 pen per month)
• High copays or coinsurance (often $200-500/month even with coverage)

Prior Authorization Process

If your insurance requires prior authorization, your provider must submit documentation showing medical necessity:

• Your BMI and weight history
• Documented comorbidities (diabetes, hypertension, etc.)
• Previous weight loss attempts and outcomes
• Clinical notes supporting medication appropriateness

Telehealth providers should assist with this process. However, prior authorizations can take 2-4 weeks to process and are sometimes denied initially, requiring appeals.

Self-Pay Options

Given insurance barriers, many patients opt to pay out-of-pocket:

Brand-Name Prices (without insurance):

• Wegovy: $1,200-1,400/month
• Ozempic: $900-1,000/month
• Mounjaro/Zepbound: $1,000-1,100/month

Savings Programs:

• Manufacturer coupons: Novo Nordisk and Eli Lilly offer savings cards that can reduce copays to $25-500/month (eligibility restrictions apply)
• Patient assistance programs: For uninsured or underinsured patients meeting income criteria

Telehealth Service Fees

In addition to medication costs, telehealth platforms charge for provider services:

Typical Fee Structures:

• Initial consultation: $99-299
• Monthly subscription (including follow-up visits): $49-199/month
• Per-visit pricing: $75-150 per consultation

What You Should Expect:

• Transparent pricing disclosed upfront
• Clear breakdown of consultation fees vs. medication costs
• Options for both insurance billing and cash pay
• No hidden fees or surprise charges

Klarity Health offers competitive pricing with transparent cost information provided before your first visit. We accept both insurance and self-pay options, and our providers work with you to find the most cost-effective treatment approach.

The Future of Telehealth Prescribing: What’s on the Horizon

Federal Regulatory Outlook

The DEA’s telehealth flexibilities for controlled substances are currently extended through December 31, 2025. While this doesn’t directly affect GLP-1 medications (which aren’t controlled), the broader telehealth regulatory environment is in flux:

Potential Permanent Rules: The DEA is expected to issue final regulations on telehealth prescribing in 2025 or early 2026. These rules may establish permanent frameworks for remote prescribing, potentially making some temporary COVID-era flexibilities standard practice.

Congressional Action: The TREATS Act, reintroduced in October 2025, would permanently authorize telehealth prescribing of certain controlled substances for addiction treatment and mental health care. If passed, this would signal strong Congressional support for expanded telehealth access across medical specialties.

Implications for Weight Loss Care: Any movement toward more flexible federal telehealth rules would likely maintain the already-permissive environment for non-controlled medications like GLP-1 agonists. The trend is toward greater access, not restriction.

State Legislative Trends

Expanding Nurse Practitioner Authority: Several states are considering legislation to grant NPs full practice authority:

• Mississippi has pending bills (2025 session) to allow NP independent practice
• Pennsylvania’s long-awaited regulations implementing NP autonomy may finally be issued
• Other ‘reduced practice’ states are under pressure to modernize scope of practice laws

Telemedicine Parity: Many states are moving toward ‘telemedicine parity’ laws requiring insurance companies to cover telehealth services at the same rate as in-person visits, which could improve access and affordability.

Interstate Licensure: Expansion of interstate compacts (like the Nurse Licensure Compact and Interstate Medical Licensure Compact) is making it easier for providers to practice across state lines, potentially reducing barriers to telehealth access.

New Medications on the Horizon

The GLP-1 space is rapidly evolving with new medications entering the pipeline:

Oral GLP-1 Agonists: Daily pill versions of semaglutide are in development, potentially offering an alternative to injections.

Triple Agonists: Next-generation medications targeting three hormone pathways (GLP-1, GIP, and glucagon) are in clinical trials, with even greater efficacy potential.

Extended Duration Formulations: Monthly or even quarterly injection formulations are being researched to improve convenience and adherence.

As new medications receive FDA approval, telehealth platforms will quickly integrate them into treatment offerings—potentially expanding options for patients who don’t respond well to current medications or prefer different administration routes.

Technology Enhancements

Telehealth platforms are incorporating new technologies to improve care:

Remote Monitoring: Connected scales and activity trackers allow providers to monitor patient progress between visits.

AI-Assisted Screening: Advanced algorithms help identify patients who may benefit from treatment and flag potential contraindications.

Virtual Dietitian Support: Integration of nutrition counseling into telehealth platforms provides comprehensive weight management beyond medication alone.

How Klarity Health Approaches GLP-1 Prescribing

At Klarity Health, we’re committed to making evidence-based obesity treatment accessible while maintaining the highest standards of medical care and regulatory compliance.

Our Approach to Patient Care

Comprehensive Evaluation: Every patient completes a thorough medical intake and meets with a licensed provider for a live video consultation. We don’t offer ‘prescription guarantees’—your provider will make an individualized determination based on your unique health profile.

State-by-State Compliance: Our platform automatically connects you with providers licensed in your state who understand and follow your state’s specific requirements for telehealth prescribing, including any in-person examination or follow-up mandates.

Ongoing Monitoring: We build regular follow-up into our care model as a medical best practice, not just to meet regulatory requirements. Your provider will track your progress, adjust treatment as needed, and provide support throughout your weight loss journey.

Lifestyle Integration: While medication can be a powerful tool, sustainable weight loss requires lifestyle changes. Our providers work with you to develop realistic nutrition and exercise goals alongside medication therapy.

Transparent Pricing and Insurance Options

We believe you should understand your costs before committing to treatment:

Insurance Accepted: We work with major insurance plans and will help you understand your coverage and any prior authorization requirements.

Self-Pay Options: For patients paying out-of-pocket, we offer clear, upfront pricing with no hidden fees. We’ll also help you explore manufacturer savings programs and assistance options.

No Surprise Billing: You’ll know the cost of consultations and prescriptions before proceeding with care.

Provider Qualifications

Klarity Health works exclusively with:

• Board-certified physicians (MD/DO)
• Licensed nurse practitioners and physician assistants
• Providers with experience in obesity medicine and weight management
• Clinicians who maintain active licenses in good standing in your state

Every provider on our platform is credentialed and verified to ensure they meet professional standards and state regulatory requirements.

Frequently Asked Questions

Is it legal to get weight loss medication prescribed through telehealth?

Yes. GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances, so federal law fully permits prescribing them via telehealth. State laws may add requirements (like an initial in-person visit in some states), but telehealth prescribing of these medications is legal nationwide when conducted by properly licensed providers following state-specific rules.

Do I need to have an in-person visit first?

It depends on your state. Many states (including California, Illinois, New York, Pennsylvania, and Washington) allow the entire process to be conducted via telehealth. However, about 10 states require at least one in-person examination—either before starting medication or within a certain timeframe afterward. Check the state-by-state table in this guide for your specific state’s requirements.

Can nurse practitioners prescribe these medications?

Yes, nurse practitioners can prescribe GLP-1 weight loss medications in all 50 states. However, the level of independence varies: in 34 states plus DC, NPs have full prescriptive authority and can prescribe independently after meeting experience requirements. In other states, NPs need physician collaboration or supervision agreements. Physician assistants can also prescribe these medications under similar state-specific rules.

How much does telehealth weight loss treatment cost?

Costs typically include: (1) Provider consultation fees, usually $99-299 for an initial visit and $49-199/month for ongoing care, and (2) Medication costs, which range from $900-1,400/month without insurance. With insurance coverage and manufacturer coupons, out-of-pocket costs can be significantly lower—sometimes as low as $25-500/month depending on your plan and eligibility.

Will my insurance cover telehealth visits for weight loss medication?

Many insurance plans now cover telehealth visits at the same rate as in-person visits. However, coverage for the medications themselves varies widely—some plans cover Wegovy with prior authorization, while others exclude weight loss drugs entirely. Medicare Part D generally does not cover weight loss medications, though it does cover diabetes medications like Ozempic when prescribed for diabetes management.

What are the qualifications for getting prescribed GLP-1 medications?

You typically need: (1) BMI ≥30, OR BMI ≥27 with weight-related health conditions (diabetes, hypertension, high cholesterol, sleep apnea), (2) to be 18 years or older (some medications approved for ages 12+), and (3) no contraindications such as personal or family history of medullary thyroid cancer, current pregnancy, or severe gastrointestinal disorders. Your provider will evaluate your individual situation during the consultation.

How long does it take to get a prescription through telehealth?

Once you complete your medical intake and consultation, prescriptions are typically sent to the pharmacy the same day (if you’re approved). However, if your state requires an in-person exam first, or if your insurance requires prior authorization, the process may take 2-4 weeks. Klarity Health works to expedite the process while ensuring all medical and regulatory requirements are met.

What if I move to a different state during treatment?

You’ll need to work with a provider licensed in your new state. Many telehealth platforms (including Klarity Health) have providers licensed

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid